冠脉介入治疗围手术期使用保肾片防治造影剂肾病的临床研究

缪晓帆; 王昉; 林欣

冠脉介入治疗围手术期使用保肾片防治造影剂肾病的临床研究

南京中医药大学附属医院，江苏南京 210029

计量
- 文章访问数: 2608
- HTML全文浏览量: 3
- PDF下载量: 1771
- 被引次数: 0
出版历程
- 收稿日期: 2018-05-19
- 刊出日期: 2018-09-10

Clinical Study on Prevention and Treatment of Contrast-Induced Nephropathy with Baoshen Tablets in Perioperative Period of Coronary Intervention

摘要

摘要: 目的观察保肾片预防冠脉介入治疗术后造影剂肾病的效果及可能机制。方法随机将80例接受冠脉介入治疗术的患者分为2组，对照组给予冠心病标准基础治疗；治疗组在对照组基础上，给予保肾片4片/次，每日3次，连服7 d。观察术前、术后24 h及术后72 h血肌酐（Scr）、尿素氮（BUN）、胱抑素C（CysC）、肾小球滤过率（eGFR）、尿N-乙酰-β-D-氨基葡萄糖苷酶（NAG）、尿β-半乳糖苷酶水平（GAL）水平。结果 2组间同时间点对比显示：治疗组与对照组术前各项肾损伤标志物水平无明显差异；术后24 h治疗组CysC水平则低于对照组（P<0.05）；术后72 h治疗组Scr、BUN、CysC、NAG、GAL水平均低于对照组（P<0.05），而治疗组eGFR水平则明显高于对照组（P<0.05）。同一组内不同时间点对比显示：对照组术后24 h CysC水平高于术前（P<0.05）；治疗组术后72 h Scr、BUN、NAG、GAL水平均低于术前（P＜0.05），eGFR水平则高于术前（P<0.05）；对照组术后72 h Scr、BUN、CysC、NAG、GAL水平均高于术前（P<0.05），eGFR水平低于术前（P<0.05）。结论在冠脉造影围手术期的病人应用保肾片，对造影剂肾病具有较好的防治作用。
- 冠心病介入 /
- 保肾片 /
- 造影剂肾病 /
- 肾损伤标志物
Abstract: OBJECTIVE To observe the effect and mechanism of Baoshen Tablets in preventing contrast-induced nephropathy after coronary intervention. METHODS 80 patients with coronary intervention were randomly divided into experimental group and control group. The control group was treated with standard basic treatment of coronary disease. The experimental group was given Baoshen Tablets， 4 tablets/time， 3 times a day on the basis of the control group. The serum creatinine (Scr)， urea nitrogen (BUN)， cystatin C (CysC)， glomerular filtration (eGFR)， urinary N-acetyl β-glucosaminidase (NAG) and urinary β-galactosidase level (GAL) levels were observed before surgery， 24 h and 72 h after surgery. RESULTS The comparison of the two groups in the same time showed that there was no significant difference in the levels of kidney injury markers before operation. After 24 h of operation， the level of CysC in experimental group was lower than that in control group (P<0.05). After 72 h of operation， the Scr， BUN， CysC， NAG， GAL in experimental group were lower than those in control group， while eGFR in experimental group was significantly higher than that in control group (P<0.05). The comparison of the same group in different time showed that CysC in control group after 24 h of operation was higher than the preoperative level (P<0.05). After 72 h of operation， the level of Scr， BUN， NAG， GAL were lower than the preoperative level (P<0.05)，while eGFR was higher than the preoperative leve in experimental group (P<0.05). In control group， after 72 h of operation， the levels of Scr， BUN， CysC， NAG and GAL were higher than the preoperative level (P<0.05)， and eGFR was lower than the preoperative level (P<0.05). CONCLUSION Baoshen Tablets can prevent and treat contrast-induced nephropathy for patients with the perioperative period of coronary intervention.
- coronary intervention /
- Baoshen Tablet /
- contrast-induced nephropathy /
- kidney injury markers

HTML全文

参考文献(11)

[1]	REAR R， BELL RM， HAUSENLOY DJ. Contrast-induced nephropathy following angiography and cardiac interventions[J]. Heart， 2016， 102(8):638-648.
[2]	LAMEIRE N， KELLUM JA. Contrast-induced acute kidney injury and renal support for acute kidney injury: a KDIGO summary[J]. Crit Care， 2013， 17(1): 205-217.
[3]	韩雅玲.2016年中国经皮冠状动脉介入治疗指南[J].中华心血管病杂志，2016，44(5):382-400.
[4]	JAMES MT， SAMUEL SM， MANNING MA， et al. Contrast-induced acute kidney injury and risk of adverse clinical outcomes after coronary angiography: a systematic review and meta-analysis[J]. Circ Cardiovasc Interv， 2013， 6(1): 37-43.
[5]	MCDONALD JS， MCDONALD RJ， COMIN J， et al. Frequency of acute kidney injury following intravenous contrast medium administration: A systematic review and meta-analysis[J]. Radiology， 2013， 267(1): 119-128.
[6]	AURELIO A， DURANTE A. Contrast-induced nephropathy in percutaneous coronary interventions: pathogenesis， risk factors， outcome， prevention and treatment[J]. Cardiology， 2014， 128(1): 62-72.
[7]	KIESSLING AH，DIETZ J，REYHER C，et al. Early postoperative serum cystatin C predicts severe acute kidney injury following cardiac surgery: A post-hoc analysis of a randomized controlled trial[J]. J Cardiothorac Surg， 2014， 9(1): 10-16.
[8]	YOUSEFZADEH G， PEZESHKI S， GHOLAMHOSSEINIAN A， et al. Plasma cystatin-C and risk of developing gestational diabetes mellitus[J]. Diabetes Metab Syndr， 2014， 8(1):33-35.
[9]	ZHANG GX， WANG XF， ZHANG P， et al. The clinical study of the Shenhuangcao-mixture treating early renal injury[J]. Chin J Inf TCM，2002，9(12): 16-17．
[10]	陈鹏，牛琳琳，朱明军，等. 中药对冠脉介入术后造影剂肾病防治的作用机制浅析[J]. 中国中西医结合杂志， 2016， 36(8): 991-993.
[11]	柳于介，马芳玉，王亿平，等. 保肾片治疗慢性肾功能衰竭气阴两虚兼湿浊证临床观察[J]. 中国实验方剂学杂志， 2011， 17(10):259-262.